Clinical Trial Update: GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a GSL Synthetase Inhibitor in combination with an immune checkpoint inhibitor and/or regorafenib for previously treated pMMR/M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• GSL Synthetase Inhibitor
• Immune checkpoint inhibitor
• Regorafenib (regorafenib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING